Navigation Links
Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
Date:2/3/2013

ZURICH, February 4, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) has been informed by Pfizer Inc. that the first patient has been dosed in a Phase 1 clinical trial with an anti-IgE vaccine, which is being developed under a license agreement between both parties. Pfizer's anti-IgE vaccine is based on Cytos' VLP ("virus-like-particle") vaccine platform.

Christian Itin , Chairman and Chief Executive Officer of Cytos, comments: "We are very pleased that Pfizer has advanced its anti-IgE vaccine to a Phase 1 clinical trial. This is an important milestone for the program and provides further evidence of the potential of Cytos' B-cell vaccine platform based on Qbeta-derived virus like particles."

Pfizer acquired world-wide exclusive rights to develop, manufacture and commercialize certain specified vaccines based on Cytos' VLP platform in 2009.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class biologic in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function and asthma control in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com

This foregoing press release may contain forward-looking statements that include words or phrases such as "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.


'/>"/>
SOURCE Cytos
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
2. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
3. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
4. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
5. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Aushon to Launch New Multiplex Immunoassay Platform
8. ZyDoc Selects Health Fidelitys REVEAL™ Natural Language Processing (NLP) Platform to Accelerate Time to Value for its MediSapien Web Services
9. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
10. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
11. WaferGen Bio-systems Launches MyDesign - Setting a New Standard in Flexibility with an Open Format High-Throughput qPCR Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The manufacturer of the ... kicking trainers to St. Jude Children’s Research Hospital to benefit families dealing with ... band designed to teach children how to kick a soccer ball correctly. The ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... provider serving families of Camas and Vancouver, WA, has announced the latest ... the National Breast Cancer Foundation and their Mammography Program, which provides free ...
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, Inc., one ... of the innovative newly improved Iso-Hip Wrap. The newly designed hip wrap ... enhances comfort and enables the patient to enjoy the benefits of cold therapy ...
(Date:5/4/2016)... , ... May 04, 2016 , ... A new collaboration ... world. The Duke Clinical Research Institute (DCRI) and analytics leader SAS will provide researchers ... data collected by the Duke University Health System. , The DCRI and SAS ...
(Date:5/4/2016)... ... May 04, 2016 , ... Slepkow Slepkow & ... one of the top website design companies to create a state of the ... to the law firm's main practice areas. These practice areas include: real estate, ...
Breaking Medicine News(10 mins):